<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34768862</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>21</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>p53 Transactivation Domain Mediates Binding and Phase Separation with Poly-PR/GR.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">11431</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms222111431</ELocationID><Abstract><AbstractText>The most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) is the presence of poly-PR/GR dipeptide repeats, which are encoded by the chromosome 9 open reading frame 72 (C9orf72) gene. Recently, it was shown that poly-PR/GR alters chromatin accessibility, which results in the stabilization and enhancement of transcriptional activity of the tumor suppressor p53 in several neurodegenerative disease models. A reduction in p53 protein levels protects against poly-PR and partially against poly-GR neurotoxicity in cells. Moreover, in model organisms, a reduction of p53 protein levels protects against neurotoxicity of poly-PR. Here, we aimed to study the detailed molecular mechanisms of how p53 contributes to poly-PR/GR-mediated neurodegeneration. Using a combination of biophysical techniques such as nuclear magnetic resonance (NMR) spectroscopy, fluorescence polarization, turbidity assays, and differential interference contrast (DIC) microscopy, we found that p53 physically interacts with poly-PR/GR and triggers liquid-liquid phase separation of p53. We identified the p53 transactivation domain 2 (TAD2) as the main binding site for PR25/GR25 and showed that binding of poly-PR/GR to p53 is mediated by a network of electrostatic and/or hydrophobic interactions. Our findings might help to understand the mechanistic role of p53 in poly-PR/GR-associated neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Usluer</LastName><ForeName>Sinem</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Department of Molecular Biology and Biochemistry, Medical University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spreitzer</LastName><ForeName>Emil</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Department of Molecular Biology and Biochemistry, Medical University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourgeois</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Department of Molecular Biology and Biochemistry, Medical University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madl</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9725-5231</Identifier><AffiliationInfo><Affiliation>Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Department of Molecular Biology and Biochemistry, Medical University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>BioTechMed-Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>W 1226</GrantID><Acronym>FWF_</Acronym><Agency>Austrian Science Fund FWF</Agency><Country>Austria</Country></Grant><Grant><GrantID>P28854</GrantID><Agency>FWF Austrian Science Fund</Agency><Country/></Grant><Grant><GrantID>I3792</GrantID><Agency>FWF Austrian Science Fund</Agency><Country/></Grant><Grant><GrantID>870454</GrantID><Agency>Austrian Research Promotion Agency</Agency><Country/></Grant><Grant><GrantID>864690</GrantID><Agency>Austrian Research Promotion Agency</Agency><Country/></Grant><Grant><GrantID>DOC-130</GrantID><Agency>FWF Austrian Science Fund</Agency><Country/></Grant><Grant><GrantID>I 3792</GrantID><Acronym>FWF_</Acronym><Agency>Austrian Science Fund FWF</Agency><Country>Austria</Country></Grant><Grant><GrantID>DK-MCD W1226</GrantID><Agency>FWF Austrian Science Fund</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064267">Intrinsically Disordered Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005454" MajorTopicYN="N">Fluorescence Polarization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064267" MajorTopicYN="N">Intrinsically Disordered Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019906" MajorTopicYN="N">Nuclear Magnetic Resonance, Biomolecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054730" MajorTopicYN="N">Protein Interaction Domains and Motifs</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015533" MajorTopicYN="N">Transcriptional Activation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">LLPS</Keyword><Keyword MajorTopicYN="N">intrinsically disordered domains</Keyword><Keyword MajorTopicYN="N">membraneless organelles</Keyword><Keyword MajorTopicYN="N">neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">p53</Keyword><Keyword MajorTopicYN="N">poly-PR/GR</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>13</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34768862</ArticleId><ArticleId IdType="pmc">PMC8583712</ArticleId><ArticleId IdType="doi">10.3390/ijms222111431</ArticleId><ArticleId IdType="pii">ijms222111431</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J.P., Brown R.H., Jr., Cleveland D.W. Decoding ALS: From genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Majounie E., Waite A., Simon-Sanchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B., Robberecht W., Van Den Bosch L. RNA toxicity in non-coding repeat expansion disorders. EMBO J. 2020;39:e101112. doi: 10.15252/embj.2018101112.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2018101112</ArticleId><ArticleId IdType="pmc">PMC6939197</ArticleId><ArticleId IdType="pubmed">31721251</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum B.D., Taylor J.P. The Role of Dipeptide Repeats in C9ORF72-Related ALS-FTD. Front. Mol. Neurosci. 2017;10:35. doi: 10.3389/fnmol.2017.00035.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00035</ArticleId><ArticleId IdType="pmc">PMC5303742</ArticleId><ArticleId IdType="pubmed">28243191</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron T.F., Bieniek K.F., Zhang Y.J., Jansen-West K., Ash P.E., Caulfield T., Daughrity L., Dunmore J.H., Castanedes-Casey M., Chew J., et al. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol. 2013;126:829&#x2013;844. doi: 10.1007/s00401-013-1192-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1192-8</ArticleId><ArticleId IdType="pmc">PMC3830741</ArticleId><ArticleId IdType="pubmed">24129584</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.B., Chen H.J., Peres J.N., Gomez-Deza J., Attig J., Stalekar M., Troakes C., Nishimura A.L., Scotter E.L., Vance C., et al. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep. 2013;5:1178&#x2013;1186. doi: 10.1016/j.celrep.2013.10.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.10.049</ArticleId><ArticleId IdType="pmc">PMC3898469</ArticleId><ArticleId IdType="pubmed">24290757</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K., Donnelly C.J., Haeusler A.R., Grima J.C., Machamer J.B., Steinwald P., Daley E.L., Miller S.J., Cunningham K.M., Vidensky S., et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61. doi: 10.1038/nature14973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14973</ArticleId><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne A.N., Zaepfel B.L., Hayes L., Fitchman B., Salzberg Y., Luo E.C., Bowen K., Trost H., Aigner S., Rigo F., et al. G4C2 Repeat RNA Initiates a POM121-Mediated Reduction in Specific Nucleoporins in C9orf72 ALS/FTD. Neuron. 2020;107:1124&#x2013;1140 e1111. doi: 10.1016/j.neuron.2020.06.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.06.027</ArticleId><ArticleId IdType="pmc">PMC8077944</ArticleId><ArticleId IdType="pubmed">32673563</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash P.E., Bieniek K.F., Gendron T.F., Caulfield T., Lin W.L., Dejesus-Hernandez M., van Blitterswijk M.M., Jansen-West K., Paul J.W., III, Rademakers R., et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77:639&#x2013;646. doi: 10.1016/j.neuron.2013.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.02.004</ArticleId><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K., Lammich S., Mackenzie I.R., Forne I., Zilow S., Kretzschmar H., Edbauer D., Janssens J., Kleinberger G., Cruts M., et al. hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. Acta Neuropathol. 2013;125:413&#x2013;423. doi: 10.1007/s00401-013-1088-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1088-7</ArticleId><ArticleId IdType="pubmed">23381195</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T., Liu Y., Banez-Coronel M., Reid T., Pletnikova O., Lewis J., Miller T.M., Harms M.B., Falchook A.E., Subramony S.H., et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl. Acad. Sci. USA. 2013;110:E4968&#x2013;E4977. doi: 10.1073/pnas.1315438110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1315438110</ArticleId><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik I., Kelley C.P., Wang E.T., Todd P.K. Author Correction: Molecular mechanisms underlying nucleotide repeat expansion disorders. Nat. Rev. Mol. Cell Biol. 2021;22:644. doi: 10.1038/s41580-021-00396-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00396-0</ArticleId><ArticleId IdType="pubmed">34230651</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitler A.D., Tsuiji H. There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS. Brain Res. 2016;1647:19&#x2013;29. doi: 10.1016/j.brainres.2016.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.04.004</ArticleId><ArticleId IdType="pmc">PMC5003651</ArticleId><ArticleId IdType="pubmed">27059391</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S., Gronke S., Niccoli T., Ridler C.E., Clayton E.L., Devoy A., Moens T., Norona F.E., Woollacott I.O.C., Pietrzyk J., et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science. 2014;345:1192&#x2013;1194. doi: 10.1126/science.1256800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1256800</ArticleId><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X., Tan W., Westergard T., Krishnamurthy K., Markandaiah S.S., Shi Y., Lin S., Shneider N.A., Monaghan J., Pandey U.B., et al. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron. 2014;84:1213&#x2013;1225. doi: 10.1016/j.neuron.2014.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.12.010</ArticleId><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook C.N., Wu Y., Odeh H.M., Gendron T.F., Jansen-West K., Del Rosso G., Yue M., Jiang P., Gomes E., Tong J., et al. C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy. Sci. Transl. Med. 2020;12 doi: 10.1126/scitranslmed.abb3774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abb3774</ArticleId><ArticleId IdType="pmc">PMC7989020</ArticleId><ArticleId IdType="pubmed">32878979</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y., Eshov A., Zhou J., Isiktas A.U., Guo J.U. C9orf72 arginine-rich dipeptide repeats inhibit UPF1-mediated RNA decay via translational repression. Nat. Commun. 2020;11:3354. doi: 10.1038/s41467-020-17129-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17129-0</ArticleId><ArticleId IdType="pmc">PMC7335171</ArticleId><ArticleId IdType="pubmed">32620797</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicic A., Mertens J., Boeynaems S., Bogaert E., Chai N., Yamada S.B., Paul J.W., III, Sun S., Herdy J.R., Bieri G., et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat. Neurosci. 2015;18:1226&#x2013;1229. doi: 10.1038/nn.4085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4085</ArticleId><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S., Bogaert E., Michiels E., Gijselinck I., Sieben A., Jovicic A., De Baets G., Scheveneels W., Steyaert J., Cuijt I., et al. Drosophila screen connects nuclear transport genes to DPR pathology in c9ALS/FTD. Sci. Rep. 2016;6:20877. doi: 10.1038/srep20877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep20877</ArticleId><ArticleId IdType="pmc">PMC4751451</ArticleId><ArticleId IdType="pubmed">26869068</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.J., Gendron T.F., Ebbert M.T.W., O&#x2019;Raw A.D., Yue M., Jansen-West K., Zhang X., Prudencio M., Chew J., Cook C.N., et al. Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Nat. Med. 2018;24:1136&#x2013;1142. doi: 10.1038/s41591-018-0071-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0071-1</ArticleId><ArticleId IdType="pmc">PMC6520050</ArticleId><ArticleId IdType="pubmed">29942091</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Z., Liu L., Tao Z., Wang R., Ren H., Sun H., Lin Z., Zhang Z., Mu C., Zhou J., et al. Motor dysfunction and neurodegeneration in a C9orf72 mouse line expressing poly-PR. Nat. Commun. 2019;10:2906. doi: 10.1038/s41467-019-10956-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-10956-w</ArticleId><ArticleId IdType="pmc">PMC6606620</ArticleId><ArticleId IdType="pubmed">31266945</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R., Lu Y., Gendron T.F., Karydas A., Tran H., Yang D., Petrucelli L., Miller B.L., Almeida S., Gao F.B. Poly(GR) in C9ORF72-Related ALS/FTD Compromises Mitochondrial Function and Increases Oxidative Stress and DNA Damage in iPSC-Derived Motor Neurons. Neuron. 2016;92:383&#x2013;391. doi: 10.1016/j.neuron.2016.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.09.015</ArticleId><ArticleId IdType="pmc">PMC5111366</ArticleId><ArticleId IdType="pubmed">27720481</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafinca R., Scaber J., Ababneh N., Lalic T., Weir G., Christian H., Vowles J., Douglas A.G., Fletcher-Jones A., Browne C., et al. C9orf72 Hexanucleotide Expansions Are Associated with Altered Endoplasmic Reticulum Calcium Homeostasis and Stress Granule Formation in Induced Pluripotent Stem Cell-Derived Neurons from Patients with Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Stem Cells. 2016;34:2063&#x2013;2078. doi: 10.1002/stem.2388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.2388</ArticleId><ArticleId IdType="pmc">PMC4979662</ArticleId><ArticleId IdType="pubmed">27097283</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer N.J., Haney M.S., Morgens D.W., Jovicic A., Couthouis J., Li A., Ousey J., Ma R., Bieri G., Tsui C.K., et al. CRISPR-Cas9 screens in human cells and primary neurons identify modifiers of C9ORF72 dipeptide-repeat-protein toxicity. Nat. Genet. 2018;50:603&#x2013;612. doi: 10.1038/s41588-018-0070-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0070-7</ArticleId><ArticleId IdType="pmc">PMC5893388</ArticleId><ArticleId IdType="pubmed">29507424</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi K.Y., Mori E., Nizami Z.F., Lin Y., Kato M., Xiang S., Wu L.C., Ding M., Yu Y., Gall J.G., et al. Toxic PRn poly-dipeptides encoded by the C9orf72 repeat expansion block nuclear import and export. Proc. Natl. Acad. Sci. USA. 2017;114:E1111&#x2013;E1117. doi: 10.1073/pnas.1620293114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1620293114</ArticleId><ArticleId IdType="pmc">PMC5320981</ArticleId><ArticleId IdType="pubmed">28069952</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes L.R., Duan L., Bowen K., Kalab P., Rothstein J.D. C9orf72 arginine-rich dipeptide repeat proteins disrupt karyopherin-mediated nuclear import. eLife. 2020;9:e51685. doi: 10.7554/eLife.51685.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.51685</ArticleId><ArticleId IdType="pmc">PMC7051184</ArticleId><ArticleId IdType="pubmed">32119645</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I., Xiang S., Kato M., Wu L., Theodoropoulos P., Wang T., Kim J., Yun J., Xie Y., McKnight S.L. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science. 2014;345:1139&#x2013;1145. doi: 10.1126/science.1254917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1254917</ArticleId><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>Conlon E.G., Lu L., Sharma A., Yamazaki T., Tang T., Shneider N.A., Manley J.L. The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. eLife. 2016;5:e17820. doi: 10.7554/eLife.17820.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.17820</ArticleId><ArticleId IdType="pmc">PMC5050020</ArticleId><ArticleId IdType="pubmed">27623008</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin S., Lopez-Gonzalez R., Kunz R.C., Gangopadhyay J., Borufka C., Gygi S.P., Gao F.B., Reed R. Evidence that C9ORF72 Dipeptide Repeat Proteins Associate with U2 snRNP to Cause Mis-splicing in ALS/FTD Patients. Cell Rep. 2017;19:2244&#x2013;2256. doi: 10.1016/j.celrep.2017.05.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.05.056</ArticleId><ArticleId IdType="pmc">PMC5653973</ArticleId><ArticleId IdType="pubmed">28614712</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekura K., Yagi T., Cammack A.J., Mahadevan J., Kuroda M., Harms M.B., Miller T.M., Urano F. Poly-dipeptides encoded by the C9ORF72 repeats block global protein translation. Hum. Mol. Genet. 2016;25:1803&#x2013;1813. doi: 10.1093/hmg/ddw052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddw052</ArticleId><ArticleId IdType="pmc">PMC4986334</ArticleId><ArticleId IdType="pubmed">26931465</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K.H., Zhang P., Kim H.J., Mitrea D.M., Sarkar M., Freibaum B.D., Cika J., Coughlin M., Messing J., Molliex A., et al. C9orf72 Dipeptide Repeats Impair the Assembly, Dynamics, and Function of Membrane-Less Organelles. Cell. 2016;167:774&#x2013;788 e717. doi: 10.1016/j.cell.2016.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.10.002</ArticleId><ArticleId IdType="pmc">PMC5079111</ArticleId><ArticleId IdType="pubmed">27768896</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y., Mori E., Kato M., Xiang S., Wu L., Kwon I., McKnight S.L. Toxic PR Poly-Dipeptides Encoded by the C9orf72 Repeat Expansion Target LC Domain Polymers. Cell. 2016;167:789&#x2013;802 e712. doi: 10.1016/j.cell.2016.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.10.003</ArticleId><ArticleId IdType="pmc">PMC5076566</ArticleId><ArticleId IdType="pubmed">27768897</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S., Bogaert E., Kovacs D., Konijnenberg A., Timmerman E., Volkov A., Guharoy M., De Decker M., Jaspers T., Ryan V.H., et al. Phase Separation of C9orf72 Dipeptide Repeats Perturbs Stress Granule Dynamics. Mol. Cell. 2017;65:1044&#x2013;1055 e1045. doi: 10.1016/j.molcel.2017.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2017.02.013</ArticleId><ArticleId IdType="pmc">PMC5364369</ArticleId><ArticleId IdType="pubmed">28306503</ArticleId></ArticleIdList></Reference><Reference><Citation>White M.R., Mitrea D.M., Zhang P., Stanley C.B., Cassidy D.E., Nourse A., Phillips A.H., Tolbert M., Taylor J.P., Kriwacki R.W. C9orf72 Poly(PR) Dipeptide Repeats Disturb Biomolecular Phase Separation and Disrupt Nucleolar Function. Mol. Cell. 2019;74:713&#x2013;728 e716. doi: 10.1016/j.molcel.2019.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2019.03.019</ArticleId><ArticleId IdType="pmc">PMC6525025</ArticleId><ArticleId IdType="pubmed">30981631</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon D.A., Smikle R., Reid M.J., Mizielinska S. Altered Phase Separation and Cellular Impact in C9orf72-Linked ALS/FTD. Front. Cell. Neurosci. 2021;15:664151. doi: 10.3389/fncel.2021.664151.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.664151</ArticleId><ArticleId IdType="pmc">PMC8096919</ArticleId><ArticleId IdType="pubmed">33967699</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubbi C.P., Milner J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 2003;22:6068&#x2013;6077. doi: 10.1093/emboj/cdg579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/cdg579</ArticleId><ArticleId IdType="pmc">PMC275437</ArticleId><ArticleId IdType="pubmed">14609953</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg M.A., Konopka A., Soo K.Y., Ito D., Atkin J.D. The DNA damage response (DDR) is induced by the C9orf72 repeat expansion in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2017;26:2882&#x2013;2896. doi: 10.1093/hmg/ddx170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx170</ArticleId><ArticleId IdType="pubmed">28481984</ArticleId></ArticleIdList></Reference><Reference><Citation>Maor-Nof M., Shipony Z., Lopez-Gonzalez R., Nakayama L., Zhang Y.J., Couthouis J., Blum J.A., Castruita P.A., Linares G.R., Ruan K., et al. p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR) Cell. 2021;184:689&#x2013;708 e620. doi: 10.1016/j.cell.2020.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.025</ArticleId><ArticleId IdType="pmc">PMC7886018</ArticleId><ArticleId IdType="pubmed">33482083</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.W., Martinez-Yamout M.A., Dyson H.J., Wright P.E. Structure of the p53 transactivation domain in complex with the nuclear receptor coactivator binding domain of CREB binding protein. Biochemistry. 2010;49:9964&#x2013;9971. doi: 10.1021/bi1012996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi1012996</ArticleId><ArticleId IdType="pmc">PMC2982890</ArticleId><ArticleId IdType="pubmed">20961098</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi S.W., Lee S.H., Kim D.H., Ahn M.J., Kim J.S., Woo J.Y., Torizawa T., Kainosho M., Han K.H. Structural details on mdm2-p53 interaction. J. Biol. Chem. 2005;280:38795&#x2013;38802. doi: 10.1074/jbc.M508578200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M508578200</ArticleId><ArticleId IdType="pubmed">16159876</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartlmuller C., Spreitzer E., Gobl C., Falsone F., Madl T. NMR characterization of solvent accessibility and transient structure in intrinsically disordered proteins. J. Biomol. NMR. 2019;73:305&#x2013;317. doi: 10.1007/s10858-019-00248-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10858-019-00248-2</ArticleId><ArticleId IdType="pmc">PMC6692294</ArticleId><ArticleId IdType="pubmed">31297688</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S., Akabayov S.R., Kessler N., Cohen L.S., Solanki J., Naider F., Kay L.E., Anglister J. The methyl (13)C-edited/(13)C-filtered transferred NOE for studying protein interactions with short linear motifs. J. Biomol. NMR. 2020;74:681&#x2013;693. doi: 10.1007/s10858-020-00340-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10858-020-00340-y</ArticleId><ArticleId IdType="pubmed">32997264</ArticleId></ArticleIdList></Reference><Reference><Citation>Odeh H.M., Shorter J. Arginine-rich dipeptide-repeat proteins as phase disruptors in C9-ALS/FTD. Emerg. Top. Life Sci. 2020;4:293&#x2013;305. doi: 10.1042/ETLS20190167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/ETLS20190167</ArticleId><ArticleId IdType="pmc">PMC7935415</ArticleId><ArticleId IdType="pubmed">32639008</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamagata K., Kanbayashi S., Honda M., Itoh Y., Takahashi H., Kameda T., Nagatsugi F., Takahashi S. Liquid-like droplet formation by tumor suppressor p53 induced by multivalent electrostatic interactions between two disordered domains. Sci. Rep. 2020;10:580. doi: 10.1038/s41598-020-57521-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-57521-w</ArticleId><ArticleId IdType="pmc">PMC6969132</ArticleId><ArticleId IdType="pubmed">31953488</ArticleId></ArticleIdList></Reference><Reference><Citation>Orti F., Navarro A.M., Rabinovich A., Wodak S.J., Marino-Buslje C. Insight into membraneless organelles and their associated proteins: Drivers, Clients and Regulators. Comput. Struct. Biotechnol. J. 2021;19:3964&#x2013;3977. doi: 10.1016/j.csbj.2021.06.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2021.06.042</ArticleId><ArticleId IdType="pmc">PMC8318826</ArticleId><ArticleId IdType="pubmed">34377363</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberti S., Gladfelter A., Mittag T. Considerations and Challenges in Studying Liquid-Liquid Phase Separation and Biomolecular Condensates. Cell. 2019;176:419&#x2013;434. doi: 10.1016/j.cell.2018.12.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.12.035</ArticleId><ArticleId IdType="pmc">PMC6445271</ArticleId><ArticleId IdType="pubmed">30682370</ArticleId></ArticleIdList></Reference><Reference><Citation>Candau R., Scolnick D.M., Darpino P., Ying C.Y., Halazonetis T.D., Berger S.L. Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity. Oncogene. 1997;15:807&#x2013;816. doi: 10.1038/sj.onc.1201244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1201244</ArticleId><ArticleId IdType="pubmed">9266967</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj N., Attardi L.D. The Transactivation Domains of the p53 Protein. Cold Spring Harb. Perspect. Med. 2017;7:a026047. doi: 10.1101/cshperspect.a026047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a026047</ArticleId><ArticleId IdType="pmc">PMC5204331</ArticleId><ArticleId IdType="pubmed">27864306</ArticleId></ArticleIdList></Reference><Reference><Citation>Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., Pavletich N.P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996;274:948&#x2013;953. doi: 10.1126/science.274.5289.948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.274.5289.948</ArticleId><ArticleId IdType="pubmed">8875929</ArticleId></ArticleIdList></Reference><Reference><Citation>Bochkareva E., Kaustov L., Ayed A., Yi G.S., Lu Y., Pineda-Lucena A., Liao J.C., Okorokov A.L., Milner J., Arrowsmith C.H., et al. Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. Proc. Natl. Acad. Sci. USA. 2005;102:15412&#x2013;15417. doi: 10.1073/pnas.0504614102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0504614102</ArticleId><ArticleId IdType="pmc">PMC1266094</ArticleId><ArticleId IdType="pubmed">16234232</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Lello P., Jenkins L.M.M., Jones T.N., Nguyen B.D., Hara T., Yamaguchi H., Dikeakos J.D., Appella E., Legault P., Omichinski J.G. Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Mol. Cell. 2006;22:731&#x2013;740. doi: 10.1016/j.molcel.2006.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2006.05.007</ArticleId><ArticleId IdType="pubmed">16793543</ArticleId></ArticleIdList></Reference><Reference><Citation>Krois A.S., Ferreon J.C., Martinez-Yamout M.A., Dyson H.J., Wright P.E. Recognition of the disordered p53 transactivation domain by the transcriptional adapter zinc finger domains of CREB-binding protein. Proc. Natl. Acad. Sci. USA. 2016;113:E1853&#x2013;E1862. doi: 10.1073/pnas.1602487113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1602487113</ArticleId><ArticleId IdType="pmc">PMC4822595</ArticleId><ArticleId IdType="pubmed">26976603</ArticleId></ArticleIdList></Reference><Reference><Citation>Ecsedi P., Gogl G., Hof H., Kiss B., Harmat V., Nyitray L. Structure Determination of the Transactivation Domain of p53 in Complex with S100A4 Using Annexin A2 as a Crystallization Chaperone. Structure. 2020;28:943&#x2013;953 e944. doi: 10.1016/j.str.2020.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2020.05.001</ArticleId><ArticleId IdType="pubmed">32442400</ArticleId></ArticleIdList></Reference><Reference><Citation>Orre L.M., Panizza E., Kaminskyy V.O., Vernet E., Graslund T., Zhivotovsky B., Lehtio J. S100A4 interacts with p53 in the nucleus and promotes p53 degradation. Oncogene. 2013;32:5531&#x2013;5540. doi: 10.1038/onc.2013.213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2013.213</ArticleId><ArticleId IdType="pubmed">23752197</ArticleId></ArticleIdList></Reference><Reference><Citation>Lill N.L., Grossman S.R., Ginsberg D., DeCaprio J., Livingston D.M. Binding and modulation of p53 by p300/CBP coactivators. Nature. 1997;387:823&#x2013;827. doi: 10.1038/42981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/42981</ArticleId><ArticleId IdType="pubmed">9194565</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez M.S., Desterro J.M., Lain S., Lane D.P., Hay R.T. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol. Cell. Biol. 2000;20:8458&#x2013;8467. doi: 10.1128/MCB.20.22.8458-8467.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.20.22.8458-8467.2000</ArticleId><ArticleId IdType="pmc">PMC102152</ArticleId><ArticleId IdType="pubmed">11046142</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Luo J., Brooks C.L., Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol. Chem. 2002;277:50607&#x2013;50611. doi: 10.1074/jbc.C200578200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C200578200</ArticleId><ArticleId IdType="pubmed">12421820</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks C.L., Gu W. Ubiquitination, phosphorylation and acetylation: The molecular basis for p53 regulation. Curr. Opin. Cell Biol. 2003;15:164&#x2013;171. doi: 10.1016/S0955-0674(03)00003-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0955-0674(03)00003-6</ArticleId><ArticleId IdType="pubmed">12648672</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller Jenkins L.M., Feng H., Durell S.R., Tagad H.D., Mazur S.J., Tropea J.E., Bai Y., Appella E. Characterization of the p300 Taz2-p53 TAD2 complex and comparison with the p300 Taz2-p53 TAD1 complex. Biochemistry. 2015;54:2001&#x2013;2010. doi: 10.1021/acs.biochem.5b00044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biochem.5b00044</ArticleId><ArticleId IdType="pmc">PMC7722985</ArticleId><ArticleId IdType="pubmed">25753752</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowell J.P., Simpson K.L., Stott K., Watson M., Thomas J.O. HMGB1-facilitated p53 DNA binding occurs via HMG-Box/p53 transactivation domain interaction, regulated by the acidic tail. Structure. 2012;20:2014&#x2013;2024. doi: 10.1016/j.str.2012.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2012.09.004</ArticleId><ArticleId IdType="pubmed">23063560</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbosa L.F., Cerqueira F.M., Macedo A.F., Garcia C.C., Angeli J.P., Schumacher R.I., Sogayar M.C., Augusto O., Carri M.T., Di Mascio P., et al. Increased SOD1 association with chromatin, DNA damage, p53 activation, and apoptosis in a cellular model of SOD1-linked ALS. Biochim. Biophys. Acta. 2010;1802:462&#x2013;471. doi: 10.1016/j.bbadis.2010.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2010.01.011</ArticleId><ArticleId IdType="pubmed">20097285</ArticleId></ArticleIdList></Reference><Reference><Citation>He F., Borcherds W., Song T., Wei X., Das M., Chen L., Daughdrill G.W., Chen J. Interaction between p53 N terminus and core domain regulates specific and nonspecific DNA binding. Proc. Natl. Acad. Sci. USA. 2019;116:8859&#x2013;8868. doi: 10.1073/pnas.1903077116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1903077116</ArticleId><ArticleId IdType="pmc">PMC6500136</ArticleId><ArticleId IdType="pubmed">30988205</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X., Dyson H.J., Wright P.E. A phosphorylation-dependent switch in the disordered p53 transactivation domain regulates DNA binding. Proc. Natl. Acad. Sci. USA. 2021;118:e2021456118. doi: 10.1073/pnas.2021456118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2021456118</ArticleId><ArticleId IdType="pmc">PMC7817127</ArticleId><ArticleId IdType="pubmed">33443163</ArticleId></ArticleIdList></Reference><Reference><Citation>Krois A.S., Dyson H.J., Wright P.E. Long-range regulation of p53 DNA binding by its intrinsically disordered N-terminal transactivation domain. Proc. Natl. Acad. Sci. USA. 2018;115:E11302&#x2013;E11310. doi: 10.1073/pnas.1814051115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1814051115</ArticleId><ArticleId IdType="pmc">PMC6275486</ArticleId><ArticleId IdType="pubmed">30420502</ArticleId></ArticleIdList></Reference><Reference><Citation>March Z.M., King O.D., Shorter J. Prion-like domains as epigenetic regulators, scaffolds for subcellular organization, and drivers of neurodegenerative disease. Brain Res. 2016;1647:9&#x2013;18. doi: 10.1016/j.brainres.2016.02.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.02.037</ArticleId><ArticleId IdType="pmc">PMC5003744</ArticleId><ArticleId IdType="pubmed">26996412</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd M.T., Vlatkovic N., Rubbi C.P. The nucleolus directly regulates p53 export and degradation. J. Cell Biol. 2011;194:689&#x2013;703. doi: 10.1083/jcb.201105143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201105143</ArticleId><ArticleId IdType="pmc">PMC3171122</ArticleId><ArticleId IdType="pubmed">21893597</ArticleId></ArticleIdList></Reference><Reference><Citation>Boija A., Klein I.A., Sabari B.R., Dall&#x2019;Agnese A., Coffey E.L., Zamudio A.V., Li C.H., Shrinivas K., Manteiga J.C., Hannett N.M., et al. Transcription Factors Activate Genes through the Phase-Separation Capacity of Their Activation Domains. Cell. 2018;175:1842&#x2013;1855 e1816. doi: 10.1016/j.cell.2018.10.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.10.042</ArticleId><ArticleId IdType="pmc">PMC6295254</ArticleId><ArticleId IdType="pubmed">30449618</ArticleId></ArticleIdList></Reference><Reference><Citation>Vranken W.F., Boucher W., Stevens T.J., Fogh R.H., Pajon A., Llinas M., Ulrich E.L., Markley J.L., Ionides J., Laue E.D. The CCPN data model for NMR spectroscopy: Development of a software pipeline. Proteins. 2005;59:687&#x2013;696. doi: 10.1002/prot.20449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.20449</ArticleId><ArticleId IdType="pubmed">15815974</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart D.S., Sykes B.D., Richards F.M. The chemical shift index: A fast and simple method for the assignment of protein secondary structure through NMR spectroscopy. Biochemistry. 1992;31:1647&#x2013;1651. doi: 10.1021/bi00121a010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi00121a010</ArticleId><ArticleId IdType="pubmed">1737021</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart D.S., Sykes B.D. The 13C chemical-shift index: A simple method for the identification of protein secondary structure using 13C chemical-shift data. J. Biomol. NMR. 1994;4:171&#x2013;180. doi: 10.1007/BF00175245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00175245</ArticleId><ArticleId IdType="pubmed">8019132</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamiola K., Acar B., Mulder F.A. Sequence-specific random coil chemical shifts of intrinsically disordered proteins. J. Am. Chem. Soc. 2010;132:18000&#x2013;18003. doi: 10.1021/ja105656t.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja105656t</ArticleId><ArticleId IdType="pubmed">21128621</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>